TY - JOUR
T1 - Persistent anti-Dra in two pregnancies
AU - Rahimi-Levene, Naomi
AU - Kornberg, Abraham
AU - Siegel, Gabriela
AU - Morozov, Valery
AU - Shinar, Eilat
AU - Asher, Orna
AU - Levene, Cyril
AU - Yahalom, Vered
PY - 2005
Y1 - 2005
N2 - The Drori (Dra) antigen is one of the ten high-prevalence antigens of the Cromer blood system, which are carried on decay-accelerating factor (DAF, CD55). The Dr(a-) phenotype was first described in a 48-year-old Jewish woman from Bukhara. Her serum contained an antibody to a high-prevalence antigen named anti-Dra. Most known individuals with the Dr(a-) phenotype are Jews from the geographic area of Bukhara, but individuals from Japan have also been described. Antibodies in the Cromer blood group system, including anti-Dra, have never been reported to cause HDN. In most of the cases with anti-Dra examined in Israel, the antibodies have been subtyped as IgG2 and IgG4. This report is of a woman with Dr(a-) phenotype and an anti-Dra titer of 256 to 512 in her serum, observed during two successive pregnancies. At birth, the RBCs of the first- and second-born child were negative and positive in the DAT, respectively, and neither manifested clinical signs of HDN. The disappearance of Cromer system antibodies, including anti-Dra in midpregnancy, has been described in a previous study. In that study, it was theorized that the antibodies in the serum of the women were adsorbed onto placental DAF. The finding of a high anti-Dra titer in two successive pregnancies in this patient, with a positive DAT for the RBCs of one of the two babies at term, differs from published reports, suggesting that a different mechanism might be involved.
AB - The Drori (Dra) antigen is one of the ten high-prevalence antigens of the Cromer blood system, which are carried on decay-accelerating factor (DAF, CD55). The Dr(a-) phenotype was first described in a 48-year-old Jewish woman from Bukhara. Her serum contained an antibody to a high-prevalence antigen named anti-Dra. Most known individuals with the Dr(a-) phenotype are Jews from the geographic area of Bukhara, but individuals from Japan have also been described. Antibodies in the Cromer blood group system, including anti-Dra, have never been reported to cause HDN. In most of the cases with anti-Dra examined in Israel, the antibodies have been subtyped as IgG2 and IgG4. This report is of a woman with Dr(a-) phenotype and an anti-Dra titer of 256 to 512 in her serum, observed during two successive pregnancies. At birth, the RBCs of the first- and second-born child were negative and positive in the DAT, respectively, and neither manifested clinical signs of HDN. The disappearance of Cromer system antibodies, including anti-Dra in midpregnancy, has been described in a previous study. In that study, it was theorized that the antibodies in the serum of the women were adsorbed onto placental DAF. The finding of a high anti-Dra titer in two successive pregnancies in this patient, with a positive DAT for the RBCs of one of the two babies at term, differs from published reports, suggesting that a different mechanism might be involved.
KW - Anti-Dr
KW - Titers in pregnancy
UR - http://www.scopus.com/inward/record.url?scp=25844464186&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 16178671
AN - SCOPUS:25844464186
SN - 0894-203X
VL - 21
SP - 126
EP - 128
JO - Immunohematology
JF - Immunohematology
IS - 3
ER -